Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Stryker Corporation (SYK) vs Tilray Brands Inc (TLRY) Price & Performance

Stryker CorporationTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Stryker Corporation vs Tilray Brands Inc — how do they compare? Stryker Corporation trades at $345.39 (market cap $133.54B), while Tilray Brands Inc trades at $4.77 (market cap $649.42M). The key difference: Stryker Corporation is far larger — about 205.6× Tilray Brands Inc's market cap, and Stryker Corporation pays a 1.01% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.

SYKTLRY
Market Cap
$133.54B$649.42M
Sector
TechnologyHealth
52-Week High
$394.34$21.00
52-Week Low
$282.58$3.88
Enterprise Value
$145.01B$816.55M
Dividend Yield
1.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Stryker Corporation

Stryker (SYK) trades at $341.17, down 1.34% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 results with a 9% organic sales growth and an EPS beat, recovering from a Q1 cyber incident. Profitability remains robust with a net income margin of 14.43% and a dividend yield supported by recent increases.

The stock offers upside potential driven by earnings momentum and product innovation like Mako RPS, but risks include competitive pressures and past cybersecurity disruptions. Analyst sentiment is strongly bullish with 74% buy ratings, though valuation multiples like a P/E of 36.08 suggest premium pricing relative to historical norms.

Tilray Brands Inc

TLRY trades at $4.77, up 7.92% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record fiscal 2026 revenue of $915 million (GlobeNewsWire, July 28, 2026) but posted a net loss. Key financials show a low P/S of 0.58 and P/B of 0.4, yet profitability remains challenged with negative net income margins and ROE.

Outlook is cautiously optimistic due to revenue growth and diversification into beverages and wellness, but high execution risk persists from consistent losses and competitive pressures. Analyst sentiment is mixed with 25% buy ratings, suggesting potential upside if profitability improves, though near-term volatility is likely.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY